Document:

EX-10.14

 Exhibit 10.14 

 
 

 
 November 16, 2016 
 Mr
Bryan W.J. CORKAL 
 1072 Keystone Trail Drive 
 Wildwood, MO
63005 
 Dear Mr Corkal, 
 On behalf of Calyxt, Inc., (the
“Company”), I am pleased to offer you a position with the Company as Chief Financial Officer. This offer letter agreement (this “Letter”) sets forth the terms of your offer which, if you accept, will govern your employment with
the Company. 
  

	1.	Certain Definitions. Certain words or phrases used in this Letter with initial capital letters will have the meanings set forth in paragraph 9 hereof. 

 

	2.	Employment. If you accept the terms of this Letter by November 21, 2016, the Company will employ you beginning on December 5, 2016 (the “Effective Date”), upon the terms and conditions set
forth in this Letter, and ending as provided in paragraph 6 hereof. Notwithstanding anything in this Letter to the contrary, you will be an at-will employee of the Company and you or the Company may terminate your employment with the Company
for any reason or no reason at any time. The period during which you are employed by the Company is referred to in this Letter as the “Employment Term.” 

 

	3.	Position and Duties. You shall serve as Chief Financial Officer of the Company and shall have the duties, responsibilities and authority consistent with an executive serving in such position, subject to the
Company’s right to expand such duties, responsibilities and authority, either generally or in specific instances. You shall devote all of your business time and attention to the performance of your duties under this Letter and will not engage
in any other business activities, without the prior consent of the Company’s Board of Directors. Notwithstanding the foregoing, you will be permitted to purchase and own less than five percent (5%) of the publicly-traded securities of any
corporation, provided that such ownership represents a passive investment and that you are not a controlling person of, or a member of a group that controls such corporation, and provided further that this ownership does not interfere with the
performance of your duties and responsibilities to the Company, including but not limited to the duties and responsibilities set forth in this Section 3. You will report to the Chief Executive Officer of Calyxt. 

  
 600 County Rd D West, Ste
8, New Brighton, MN 55112 
 (651) 683-2803 

www.calyxt.com 

 

 
  
  

	4.	Place of Employment and Permanent Residence. 

  

	 	(a)	The principal place of your employment will be the Company’s office in New Brighton, Minnesota, except that you may be required to travel on Company business during your employment. 

 

	 	(b)	Given the importance and nature of your position as Chief Financial Officer of Calyxt, and the Company’s business need for you to reside near its office in New Brighton, Minnesota, you agree to relocate your
permanent, full-time domicile to a residence within fifty (50) miles by car of the Company’s headquarters no later no later than June 30, 2017. The terms related to such relocation are set forth on the attached Exhibit A.

  

	5.	Compensation and Benefits. 

  

	 	(a)	Salary. The Company shall pay you an annualized salary of $220,000 (the “Base Salary”) during the Employment Period in periodic installment in accordance with the Company’s payroll practices as may
be in effect from time to time, but not less frequently than monthly. Your Base Salary will be subject to review at least annually by the Board and the Board may, but will not be required to, increase your Base Salary during the Employment Term.

  

	 	(b)	Annual Performance Bonus. For each calendar year of the Employment Term, you will be eligible to receive an annual performance bonus (“Annual Performance Bonus”) from the Company, with the target amount
of such bonus equal to thirty percent (30%) of your Base Salary. You will be eligible to this Annual Performance Bonus program, starting year 2017. Your Annual Performance Bonus will be based on achievement of individual and/or Company
performance goals that are established by the Board in its sole discretion at the beginning of each calendar year. Following the close of each calendar year, the Board shall determine whether you have earned an Annual Performance Bonus, and the
amount of any such bonus, based on the goals established at the beginning of the year. Payment of the Annual Performance Bonus is expressly conditioned upon your employment with the Company on the date the Annual Performance Bonus is paid, except as
provided in paragraph 6(e) below and as provided in paragraph 6(d) in case of Termination Without Cause (as defined in paragraph 9) and conditions detailed in paragraph 7(b)(i). The Annual Performance Bonus will be paid within seventy-five
(75) days after the end of the calendar year to which it relates. Your target Annual Performance Bonus will be subject to periodic review and adjustment by the Board, in its sole discretion, from time to time. 

  
 Page 2 of 17 

 

 
  
  

	 	(c)	Equity Award. You will be eligible to participate in and receive stock option or equity award grants under the Company’s equity incentive plan from time to time in the sole discretion of the Board, and in
accordance with the terms and conditions of such plans. 

  

	 	(d)	Executive Benefits Package. You will be entitled during your employment to participate in the Company’s Executive Benefits Package. The Company’s “Executive Benefits Package” means those
benefits (including benefits for which substantially all of the employees of the Company are from time to time generally eligible), as determined from time to time by the Company’s Board of Directors (the “Board”). The Company
reserves the right to amend or cancel any employee benefit plans, programs, or practices at any time in its sole discretion, subject to the terms of the employee benefit plan and applicable law. 

 

	 	(e)	Vacation. During the Employment Period, you will be entitled to take paid vacation pursuant to the Company’s existing policies regarding paid vacations. You will be entitled to accrue twenty (20) days
of paid vacation per calendar year. Beginning on the Effective Date, your vacation time will accrue on a monthly basis at a rate of 1.67 days per month. Vacation time that is not used by you in the calendar year it accrues may be carried over to the
next calendar year, but you will cease to accrue additional vacation time beyond your annual accrual (i.e., 20 days) in any calendar year until you have taken vacation and your accrued vacation time has dropped below the maximum annual accrual of 20
days. 

  

	6.	Termination Events. 

 Your employment with the Company will continue until terminated
upon the occurrence of any of the following events: 
  

	 	(a)	Your death; 

  

	 	(b)	Your Permanent Disability; 

  

	 	(c)	Your written notice of your termination of your employment to the CEO; 

  

	 	(d)	The termination of your employment by the Company at any time Without Cause (as defined in paragraph 9) with the termination to take effect as determined by the Company; or 

 

	 	(e)	The termination of your employment by the Company For Cause (as defined in paragraph 9), with the termination to take effect immediately upon written notice by the Company to the Employee or upon a date determined by
the Company. 

  
 Page 3 of 17 

 

 
  
  

	7.	Consequences of Termination. 

  

	 	(a)	Compensation upon Termination by Company – For Cause. Upon the termination of your employment For Cause, you will cease to have any rights to Base Salary, bonus awards, expense reimbursements, fringe
benefits or any other compensation or benefits of any nature, except that you will be entitled to receive any Base Salary that has accrued but is unpaid, any reimbursable expenses that have been incurred but are unpaid, and any unused vacation days
that have accrued under the Company’s vacation policy, as of your Termination Date, which will be paid in accordance with Company’s usual payroll procedures. (collectively, the “Accrued Amounts”). 

 

	 	(b)	Compensation upon Termination by Company – Not For Cause. 

  

	 	(i)	Upon the termination Without Cause of your employment provided for in paragraph 6(d), you will cease to have any rights to Base Salary, bonus awards, expense reimbursements, fringe benefits or any other compensation or
benefits of any nature, except that you will be entitled to receive the Accrued Amounts and Annual Performance Bonus on a prorata temporis basis. 

  

	 	(ii)	So long as you are complying with the non-compete and other applicable obligations set forth in this agreement, the Company shall continue to pay you Severance Pay in an amount equal to twelve (12) months of Base
Salary at a rate in effect on the date of termination, reduced by any required federal, state and local taxes and any other applicable withholdings or deductions, with the Company’s payment of such salary continuation payable in periodic
installments in accordance with the Company payroll practices. You agree and acknowledge that the Company may condition the receipt of any Severance Pay due to you pursuant to this paragraph upon: (i) you entering into a full release of claims
in favour of the Company, its affiliates and subsidiaries and their respective officers and directors and separation agreement in such form as to be provided by the Company and (ii) such general release becomes effective within twenty-one
(21) business days after the day it is provided to you for execution, and is not thereafter revoked by you, and provided further that you comply with all terms and conditions of this separation agreement, you will receive the benefit to which
you are entitled. In the event the Company invokes its non-compete option as provided for in paragraph 8(b), your severance payment will end and the other terms and conditions of this separation agreement will continue. 

 

	 	(c)	Compensation upon Termination – By You. Upon your voluntary termination of your employment provided for in paragraph 6(c), you will cease to have any rights to Base Salary, bonus awards, expense
reimbursements, fringe benefits or any other compensation or benefits of any nature, except that you will be entitled to receive the Accrued Amounts. 

  
 Page 4 of 17 

 

 
  
  

	 	(d)	Compensation Upon Termination – Death or Permanent Disability. In the event your employment is terminated because of death or Permanent Disability, you will cease to have any rights to Base Salary, bonus
awards, expense reimbursements, fringe benefits or any other compensation or benefits of any nature, except that you will be entitled to receive the Accrued Amounts. In the event your employment is terminated as a result of your death, your spouse
or, if you are not married at the time of your death, your estate will be entitled to the Accrued Amounts. 

  

	8.	Competitive Activity; Confidentiality; Non-Solicitation; Discoveries and Inventions; Works Made for Hire. 

  

	 	(a)	Acknowledgements and Agreements. You hereby acknowledge and agree that in the performance of your duties to the Company, you will be brought into frequent contact with existing Customers and Potential Customers
of the Company throughout the world. You agree that trade secrets and confidential information of the Company, more fully described in subparagraph 8(e)(i), gained by you during your association with the Company, have been developed by the Company
through substantial expenditures of time, effort and money and constitute valuable and unique property of the Company. You further understand and agree that the foregoing makes it necessary for the protection of the Company’s Business that you
do not compete with the Company during your employment with the Company and that you do not compete with the Company for a reasonable period thereafter, as further provided in the following subparagraphs. 

 

	 	(b)	Competitive Activity. 

  

	 	(i)	While employed by the Company, and for a period of one (1) year following your Termination Date, you are obligated to provide notice to Cayxt of future activity and responsibilities (as provided for in subparagraph
8(b)(ii)) prior to starting a new position. Upon receipt of such notice, the Company will have a 10-day window to exercise a non-compete for a period not to exceed 12 months from the Termination Date. In such event, the Company will pay you your
base salary according to the Company payroll schedule less applicable withholdings. In the even (i) you are terminated without cause by the Company, (ii) the Company is paying a severance payment to you, and (iii) the Company invokes
its non-compete option, your severance payments will end and the non-compete payment will begin for a period not to exceed one year from Termination Date. In the event you breach this clause, you agree to reimburse immediately all severance and
non-compete payments you received from the Company. 

  
 Page 5 of 17 

 

 
  
  

	 	(ii)	Direct or Indirect Competition. For the purpose of subparagraph 8(b)(i) but without limitation thereof, you will be in violation thereof if you engage in any or all of the activities set forth therein directly as an
individual on your own account, or indirectly as a partner, joint venturer, employee, agent, salesperson, consultant, officer and/or director of any firm, association, partnership, corporation or other entity, or as a stockholder of any corporation
in which you or your spouse, child or parent owns, directly or indirectly, individually or in the aggregate, more than five percent of the outstanding stock. 

  

	 	(iii)	If it is judicially determined that you have violated subparagraph 8(b)(i), then the period applicable to each obligation that you have been determined to have violated will automatically be extended from the date of
judicial determination by a period of time equal in length to the period during which such violation(s) occurred. 

  

	 	(c)	The Company. For purposes of this subparagraph 8(c), the Company will include any and all direct and indirect subsidiary, parent, affiliated, or related companies of the Company for which you worked or had
responsibility at the time of termination of your employment and at any time during the two-year period prior to such termination. 

  

	 	(d)	Non-Solicitation. 

  

	 	(i)	Of Customers. You will not directly or indirectly at any time during the period of your employment or for a period of twenty-four (24) months following your Termination Date, directly or indirectly, solicit,
divert, or take away or supervise any other person, firm, or other entity in soliciting, diverting, or taking away any Customer or Prospective Customer of the Company for the purpose of selling, performing or providing Business Services to that
Customer or Prospective Customer. 

  

	 	(ii)	Of Employees. You will not, directly or indirectly, at any time during the period of your employment or for a period of twenty-four (24) months following your Termination Date solicit, hire, employ, engage,
affiliate with for profit, retain (or assist any other person or entity in soliciting, hiring, employing, engaging, affiliating for profit or retaining) any person who was a Company employee or consultant or independent contractor at any time during
the one (1)-year period prior to your soliciting, hiring, employing, engaging, affiliating for profit or retaining, whether for your benefit or the benefit of any other person or organization other than the Company, or solicit, induce, or encourage
any such person to terminate or leave the Company’s employ, engagement, or other remunerative relationship with the Company. You acknowledge that this covenant is necessary to enable the Company to maintain a stable workforce and remain in
business. 

  
 Page 6 of 17 

 

 
  
  

	 	(e)	Confidentiality. 

  

	 	(i)	You will keep in strict confidence, and will not, directly or indirectly, at any time, during or after your employment with the Company, disclose, furnish, disseminate, make available or, except in the course of
performing your duties of employment, use any trade secrets or confidential business and technical information of the Company or its Customers, suppliers or vendors, without limitation as to when or how you may have acquired such information. Such
confidential information will include, without limitation, all information belonging to the Company, its affiliates, subsidiaries, or any other person or entity that has entrusted information to the Company in confidence, technology, computer
programs or programming, systems, software, software codes, designs, data bases, trade secrets, know-how, research, methods, manuals, records, product or service ideas or plans, work-in-progress, results, algorithms, inventions, developments,
original works of authorship, discoveries, experimental processes, experimental results, unpublished patent applications, laboratory notebooks, processes, formulas, investigation or research techniques, engineering designs and drawings, hardware
configuration information, regulatory information, medical reports, clinical data and analysis reagents, cell lines, biological materials, chemical formulas, financial information including but not limited to price lists, pricing methodologies, cost
data, financial forecasts, historical financial data, and budgets, marketing information, including but not limited to market share data, marketing plans, licenses, business plans, lists of the needs and preferences of Customers and Prospective
Customers, promotional materials, training courses and other training and instructional materials, vendor and product information, all agreements with third parties and terms of agreements, transactions and potential transactions, negotiations,
information relating to employees and consultants of the Company, including names, contact information, and expertise, lists of or information relating to suppliers and vendors and other business information disclosed by the Company (whether by
oral, written, graphic or machine-readable format) which confidential information is designated in writing to be confidential or proprietary, or if given orally, is confirmed in writing as having been disclosed as confidential or proprietary within
a reasonable time (not to exceed 30 days after the oral disclosure), or which information would, under the circumstances appear to a reasonable person to be confidential or proprietary. 

  
 Page 7 of 17 

 

 
  
  

	 	(ii)	You specifically acknowledge that all such confidential information, whether reduced to writing, maintained on any form of electronic media, or maintained in your mind or memory and whether compiled by the Company,
and/or you, derives independent economic value from not being readily known to or ascertainable by proper means by others who can obtain economic value from its disclosure or use, that reasonable efforts have been made by the Company to maintain the
secrecy of such information, that such information is the sole property of the Company and that any retention and your use of such information during your employment with the Company (except in the course of performing your duties and obligations to
the Company) or after the termination of your employment will constitute a misappropriation of the Company’s trade secrets. 

  

	 	(iii)	You agree that upon termination of your employment with the Company, for any reason, you will return to the Company, in good condition, all property of the Company, including without limitation, the originals and all
copies of any documents in whatever form (electronic, hard copy, etc.) or materials which contain, reflect, summarize, describe, analyze or refer or relate to any items of information listed in subparagraph 8(e)(i) of this Letter. You agree that all
confidential information, as listed in subparagraph 8(e)(i) of this Letter is the sole property of the Company and you have no right, title or interest to this property. In the event that such items are not so returned, the Company will have the
right to charge you for all reasonable damages, costs, attorneys’ fees and other expenses incurred in searching for, taking, removing and/or recovering such property. 

 

	 	(iv)	Notwithstanding the above, you will have no liability to the Company with regard to any confidential information you can prove was in the public domain at the time it was disclosed or entered the public domain through
no fault of yours. 

  

	 	(f)	Discoveries and Inventions; Work Made for Hire. 

  

	 	(i)	 You agree that upon conception and/or development of any idea, discovery, invention, improvement, software,
writing or other material or design that: (A) relates to the business of the Company, or (B) relates to the Company’s actual or demonstrably anticipated research or development, or (C) results from any work performed by you for
the Company, you will assign to the Company the entire right, title and interest in and to any such idea, discovery, invention, improvement, software, writing or other material or design. (together, “Discoveries and Inventions”) Subject to
the requirements of applicable state law, if any, you understand that Discoveries and Inventions will not include, and the provisions of this Letter will not apply to any idea, discovery, invention,

  
 Page 8 of 17 

 

 
  
  

	 	
improvement, software, writing or other material or design that qualifies fully for exclusion under the provisions of applicable state law. You also agree that any idea, discovery, invention,
improvement, software, writing or other material or design that relates to the business of the Company or relates to the Company’s actual or demonstrably anticipated research or development which is conceived or suggested by you, either solely
or jointly with others, within one year following termination of your employment under this Letter or any successor agreements will be presumed to have been so made, conceived or suggested in the course of such employment with the use of the
Company’s equipment, supplies, facilities, and/or trade secrets. 

  

	 	(ii)	 You agree that during your employment, and for one year after termination of your employment under this Letter or
any successor agreements, you will disclose immediately and fully to the Company any Discovery and Invention conceived, made or developed by you solely or jointly with others. The Company agrees to keep any such disclosures confidential. You also
agree to record descriptions of all work in the manner directed by the Company, agree that all such records and copies, samples and experimental materials will be the exclusive property of the Company, and agree not to remove these records from the
Company’s place of business except as expressly permitted by Company policy which may, from time to time, be revised at the sole election of the Company for the purpose of furthering the Company’s business. You agree that at the request of
and without charge to the Company, but at the Company’s expense, you will execute a written assignment of the idea, discovery, invention, improvement, software, writing or other material or design to the Company and will assign to the Company
any application for letters patent or for trademark registration made thereon, and to any common-law or statutory copyright therein; and that you will do whatever may be necessary or desirable to enable the Company to secure any patent, trademark,
copyright, or other property right therein in the United States and in any foreign country, and any division, renewal, continuation, or continuation in part thereof, or for any reissue of any patent issued thereon. In the event the Company is
unable, after reasonable effort, and in any event after ten business days, to secure you signature on a written assignment to the Company of any application for letters patent or to any common-law or statutory copyright or other property right
therein, whether because of your physical or mental incapacity or for any other reason whatsoever, you irrevocably designate and appoint the General Counsel of the Company as your attorney-in-fact to act on your behalf to execute and file any such
application and to do all other lawfully permitted acts to further the prosecution and issuance of such letters patent, copyright or trademark. Any assignment of the rights to an idea, discovery, invention, improvement, software, writing or

  
 Page 9 of 17 

 

 
  
  

	 	
other material or design includes all rights of attribution, paternity, integrity, modification, disclosure and withdrawal, any other rights throughout the world that may be known or referred to
as “moral rights,” “artists rights,” “droit moral,” or the like. (“Moral Rights”) To the extent that Moral Rights cannot be assigned under applicable law, you hereby waive and agree not to enforce any and all
Moral Rights, including, without limitation, any limitation on subsequent modification, to the extent permitted under applicable law. 

  

	 	(iii)	You acknowledge that, to the extent permitted by law, all work papers, reports, documentation, drawings, photographs, negatives, tapes and masters therefor, prototypes and other materials (hereinafter,
“items”), including without limitation, any and all such items generated and maintained on any form of electronic media, generated by you during your employment with the Company will be considered a “work made for hire” and that
ownership of any and all copyrights in any and all such items will belong to the Company. The item will recognize the Company as the copyright owner, will contain all proper copyright notices, e.g., “(creation date), All Rights Reserved,”
and will be in condition to be registered or otherwise placed in compliance with registration or other statutory requirements throughout the world. 

  

	 	(g)	Communication of Contents of Letter. While employed by the Company and for one year thereafter, you will communicate the contents of paragraph 8 of this Letter to any person, firm, association, partnership,
corporation or other entity that you intend to be employed by, associated with, or represent. 

  

	 	(h)	Confidentiality Agreements. You agree that you will not disclose to the Company or induce the Company to use any secret or confidential information belonging to your former employers. Except as indicated, you
warrant that you are not bound by the terms of a confidentiality agreement or other agreement with a third party that would preclude or limit your right to work for the Company and/or to disclose to the Company any ideas, inventions, discoveries,
improvements or designs or other information that may be conceived during employment with the Company. You agree to provide the Company with a copy of any and all agreements with a third party that preclude or limit your right to make disclosures or
to engage in any other activities contemplated by your employment with the Company. 

  

	 	(i)	Relief. You acknowledge and agree that the remedy at law available to the Company for breach of any of your obligations under this Letter would be inadequate. You therefore agree that, in addition to any other
rights or remedies that the Company may have at law or in equity, temporary and permanent injunctive relief may be granted in any proceeding which may be brought to enforce any provision contained in subparagraphs 8(b), 8(d), 8(e), 8(f), 8(g) and
8(h) inclusive, of this Letter, without the necessity of proof of actual damage or the need to post a bond. 

  
 Page 10 of 17 

 

 
  
  

	 	(j)	Reasonableness. You acknowledge that your obligations under this paragraph 8 are reasonable in the context of the nature of the Company’s Business and the competitive injuries likely to be sustained by the
Company if you were to violate such obligations. You further acknowledge that this Letter is made in consideration of, and is adequately supported by the agreement of the Company to perform its obligations under this Letter and by other
consideration, which you acknowledge constitutes good, valuable and sufficient consideration. 

  

	9.	Definitions. 

  

	 	(a)	“Customer” means any client, customer or account, including, but not limited to any person, firm, corporation, association or other business entity of any kind to which the Company has provided or is
providing products or services. 

  

	 	(b)	“Company’s Business” means the research, development, and/or commercialization of products and services based on gene-editing technologies in the field of agriculture, food and plant sciences,
which is to be construed to include all research, development, and/or commercialization of products and services as may hereinafter evolve within the gene editing field or is in planning or developmental stages at the Company. 

 

	 	(c)	“Permanent Disability” means that, because of accident, disability, or physical or mental illness, you are incapable of performing your duties to the Company or any subsidiary, as determined by the
Board. Notwithstanding the foregoing, you will be deemed to have become incapable of performing your duties to the Company or any subsidiary, if you are incapable of so doing for (i) a continuous period of 90 days and remain so incapable at the
end of such 90 day period or (ii) periods amounting in the aggregate to 180 days within any one period of 365 days and remain so incapable at the end of such aggregate period of 180 days. 

 

	 	(d)	“Prospective Customer” means any prospective client, customer or account, including, without limitation, any person, firm, corporation, association or other business entity of any kind with which the
Company had any negotiations or substantial discussions regarding the possibility of providing products or services within the one (1) year period preceding your Termination Date 

 

	 	(e)	“Section 409A” means Section 409A of the Internal Revenue Code of 1986, as amended, and any guidance issued thereunder. 

  
 Page 11 of 17 

 

 
  
  

	 	(f)	“Termination Date” means the effective date of your termination of employment with the Company. 

  

	 	(g)	“Termination For Cause” means the termination by the Company of your employment with the Company or any subsidiary as a result of (i) your conviction of or plea of guilty or nolo contendere to a
crime that constitutes a felony or a crime that constitutes a misdemeanor involving moral turpitude; (ii) your engagement in an act of fraud, dishonesty, or unauthorized disclosure of Confidential Information (as defined in this Letter);
(iii) your failure or refusal to comply with any valid and legal directive of the Board of Directors; (iv) your gross negligence or willful misconduct with respect to the Company or any subsidiary or affiliate of the Company; (v) your
failure or refusal to perform your duties and responsibilities as Chief Financial Officer, (other than such failure resulting from incapacity due to physical or mental illness) which is not cured within five (5) days after written notice
thereof to you; (vi) your material failure to comply with the Company’s written policies or rules, as they may be in effect from time to time during your employment, which is not cured within five (5) days after written notice thereof
to you; or (vii) your material breach of this Letter or any other agreement with the Company, which is not cured within thirty (30) days after written notice thereof to you. 

 

	 	(h)	“Termination Without Cause” means the termination by the Company of your employment with the Company for any reason other than a termination for Permanent Disability, death, or a Termination for Cause.

  

	10.	Section 409(A). 

  

	 	(a)	General Compliance. This Letter is intended to comply with Section 409(A) or an exemption thereunder and will be construed and administered in accordance with Section 409(A). Notwithstanding any other
provision of this Letter, payments provided under this Letter may only be made upon an event and in a manner that complies with Section 409(A) or an applicable exemption. Any payments under this Letter that may be excluded from
Section 409(a) either as separation pay provided due to an involuntary separation from service or as a short-term deferral will be excluded from Section 409(A) to the maximum extent possible. For purposes of Section 409(A), each
installment payment provided under this Letter will be treated as a separate payment. Any payments to be made under this Letter upon a termination of employment will only be made upon a “separation from service” under Section 409A.
Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Letter comply with Section 409A and in no event will the Company be liable for all or any portion of any taxes, penalties,
interest or other expenses that may be incurred by you on account of non-compliance with Section 409A. 

  
 Page 12 of 17 

 

 
  
  

	 	(b)	Specified Employees. Notwithstanding any other provision of this Letter, if any payment or benefit provided to you in connection with your termination of employment is determined to constitute “non-qualified
deferred compensation” within the meaning of Section 409A and you are determined to be a “specified employee” at that time as defined in Section 409A(a)(2)(b)(i), then such payment or benefit will not be paid until the first
payroll date to occur following the six-month anniversary of the Termination Date (the “Specified Employee Payment Date”) or, if earlier, on your death. The aggregate of any payments that would otherwise have been paid before the Specified
Employee Payment Date (and interest on such amounts calculated based on the applicable federal rate published by the Internal Revenue Service for the month in which your separation from service occurs shall be paid to the you in lump sum on the
specified Employee Payment date and thereafter, any remaining payments will be paid without delay in accordance with their original schedule. 

  

	11.	Representations. As of the Effective Date, you represent and warrant to the Company that: 

  

	 	(a)	Your acceptance of employment with the Company and your performance of the duties and responsibilities under this Letter will not conflict with or result in a violation of, a breach of, or a default under any contract,
agreement or understanding to which he is a party or otherwise bound. 

  

	 	(b)	Your acceptance of employment with the Company and the performance of your duties and responsibilities under this Letter will not violate any non-solicitation, non-competition or other similar covenant or agreement of a
prior employer. 

  

	12.	Survival. Upon the termination of this Letter, the respective rights and obligations of the parties hereto will survive this termination to the extent necessary to carry out the intention of the parties to this
Letter. 

  

	13.	Taxes. The Company may withhold from any amounts payable under this Letter all federal, state, city or other taxes as the Company is required to withhold pursuant to any applicable law, regulation or ruling.
Notwithstanding any other provision of this Letter, the Company will not be obligated to guarantee any particular tax result for you with respect to any payment provided to you hereunder, and you will be responsible for any taxes imposed on you with
respect to any such payment. 

  
 Page 13 of 17 

 

 
  
  

	14.	Notices. Any notice provided for in this Letter will be in writing, with a copy to respective individual email addresses, and will be either personally delivered, sent by reputable overnight carrier or mailed by
first class mail, return receipt requested, to the recipient at the address below indicated: 

 Notices to You: 

Mr Bryan W.J. CORKAL 
 1072
Keystone Trail Drive 
 Wildwood, MO 63005 

Notices to the Company: 

Mr. Federico TRIPODI, CEO 

Calyxt, Inc. 
 600 County Road D
STE 8 
 New Brighton, MN 55112 

or such other address or to the attention of such other person as the recipient party will have specified by prior written notice to the
sending party. Any notice under this Letter will be deemed to have been given when so delivered. 
  

	15.	Severability. Whenever possible, each provision of this Letter will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Letter is held to be invalid or
unenforceable in any respect under any applicable law, such invalidity or unenforceability will not affect any other provision, but this Letter will be reformed, construed and enforced as if such invalid or unenforceable provision had never been
contained herein. Should a determination be made by the Court designated in paragraph 20 hereof that the character, duration, or geographical scope of paragraph 8 of the Letter is unreasonable in light of the circumstances as they then exist, then
it is the intention and the agreement of the parties to the Letter that the provision be construed by the Court in such a manner as to impose only those restrictions on the parties that are reasonable in light of the circumstances as they then exist
and as are necessary to assure the parties of the intended benefit of the Letter. If, in any judicial proceeding, the Court refuses to enforce all of the separate provisions included in the Letter because, taken together, they are more extensive
than necessary to assure the parties of the intended benefit of the Letter, those provisions which, if eliminated, would permit the remaining separate provisions to be enforced in such proceeding, will, for the purpose of such proceeding, be deemed
eliminated from the Letter. 

  
 Page 14 of 17 

 

 
  
  

	16.	Prevailing Party’s Litigation Expenses. In the event of litigation between you and the Company related to this Letter, the non-prevailing party will reimburse the prevailing party for any costs and expenses
(including, without limitation, attorneys’ fees) reasonably incurred by the prevailing party in connection therewith. 

  

	17.	Complete Agreement. This Letter embodies the complete agreement and understanding between the parties with respect to the subject matter hereof and effective as of its date supersedes and preempts any prior
understandings, agreements or representations by or between the parties, written or oral, which may have related to the subject matter hereof in any way. 

  

	18.	Counterparts. This Letter may be executed in separate counterparts, each of which will be deemed to be an original and both of which taken together will constitute one and the same agreement. 

 

	19.	Successors and Assigns. This Letter will bind and inure to the benefit of and be enforceable by you, the Company and your and the Company’s respective heirs, executors, personal representatives, successors
and assigns, except that neither party may assign any rights or delegate any obligations hereunder without the prior written consent of the other party. You hereby consent to the assignment by the Company of all of its rights and obligations
hereunder to any successor to the Company by merger or consolidation or purchase of all or substantially all of the Company’s assets, provided such transferee or successor assumes the liabilities of the Company hereunder. 

 

	20.	Governing Law. This Letter will be governed by, and construed in accordance with, the internal, substantive laws of the State of Minnesota. You agree that the state and federal courts located in the State of
Minnesota, without regard to or application of conflict of laws principles, will have jurisdiction in any action, suit or proceeding against you based on or arising out of this Letter and you hereby: (a) submit to the personal jurisdiction of
such courts; (b) consent to service of process in connection with any action, suit or proceeding against you; and (c) waive any other requirement (whether imposed by statute, rule of court or otherwise) with respect to personal
jurisdiction, venue or service of process. 

  

	21.	Amendment and Waiver. The provisions of this Letter may be amended or waived only with the prior written consent of you and the Company, and no course of conduct or failure or delay in enforcing the provisions of
this Letter will affect the validity, binding effect or enforceability of this Letter. 

  
 Page 15 of 17 

 

 
  
  

	22.	Acknowledgement of Full Understanding. I acknowledge and agree that I have fully read and understand this Letter, and I have had the opportunity to ask questions and consult with an attorney of my choice before
signing this Letter. 

 If these terms are acceptable to you, please sign and date this Letter in the appropriate space below and return it to
me as soon as possible. We look forward to you becoming a part of our team. 
 Please call me with any questions. 

Sincerely, 
  

	
	
	/s/ Federico Tripodi
	Federico TRIPODI, CEO

			
		
	Date:	 	November 16, 2016

	
	
	Agreed and Accepted:
	
	/s/ Bryan Corkal

  

			
		
	Date:	 	November 17, 2016

  
 Page 16 of 17 

 

 
  
  

 EXHIBIT A 

If you relocated your primary residence to within fifty (50) miles of the Company’s headquarters, on or before June 30, 2017, the Company will
provide the following relocation allowances described in (i) below and the following temporary living and transition expenses described in (ii), upon satisfaction of the additional conditions described in (iii) and (iv). 

 

	 	(i)	Relocation Allowance. The Company shall provide a lump sum of $30,000, paid after relocation is complete. 

  

	 	(ii)	Temporary living and transition expenses. For up to June 30, 2017, the Company will reimburse you up to $20,000, following the Company expenses policy. The eligible temporary living and transition expenses
incurred while living within fifty (50) miles of the Company’s headquarter and prior relocation to the new residence are as follow: housing hunting trip for direct family and costs associated during the purchase of a house, furnished
long-term stay facility (a Residence Inn style facility) or rental home (including utilities), mileage or airfare to St. Louis for 3 trips per month (on weekends), meals, laundry, rental car and storage of household goods. 

 

	 	(iii)	Relocation repayment. If you voluntarily terminate employment within 36 months of the Effective Date, you will reimburse relocation payments on prorated basis. 

 

	 	(iv)	Relocation timeline. You must relocate your permanent residence to New Brighton area by June 30, 2017. If you have not substantially completed relocation of your full time residence to within no less fifty
(50) miles of the Calyxt headquarters in New Brighton, MN on or before June 30, 2017, then you will repay above payments. This payment shall be made to Calyxt in a single sum on or before July 15, 2017. 

  
 Page 17 of 17EX-10.15

 Exhibit 10.15 

CONSULTING AGREEMENT 

This Consulting Agreement (this “Agreement”) is made as of January 1st, 2010 (the “Effective Date”) by and between Cellectis Plant Sciences, Inc., a Delaware corporation (“Client”), and Daniel F. Voytas, an individual
residing at 2197 FOL WELL A VENUE, FALCON HEIGHTS, MN 55108 USA, (“Consultant”). 
 RECITALS

 WHEREAS, Client specializes in Meganuclease technology for use in plant research and the
development of products for use in agriculture (“Client Business”);  
 WHEREAS, Consultant is
the Director of the Center for Genome Engineering at the University of Minnesota;  
 WHEREAS, Client desires to engage
Consultant to provide certain services including without limitation, strategic planning services and analyses (the “Services”); and  

WHEREAS, Consultant is willing to provide such Services on the terms and conditions set out below.  

NOW, THEREFORE, for good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties agree as follows: 

 1. Services. In consideration for the Consultation Fee set forth in Section 2(a) below, Consultant agrees
to provide the Services as described in Exhibit A (“Services Description”). The parties may amend the Services Description from time to time; each such amendment shall be attached hereto as an additional exhibit and
incorporated herein by reference. 
 2. Payment. 

(a) Consultation Fees. As compensation for the performance of the Services during the Term (as defined in Section 6(a) below),
Client will pay Consultant a consultation fee (the “Consultation Fee”) as set forth in the table below: 

							
	 Dates
	  	 Average Day Worked
	  	Consultation Fee	 
	 January 1, 2010 – June 30, 2010
	  	1 day per week	  	$	5,000	 
	 July 1, 2010 – June 30, 2011
	  	10 days per month	  	$	12,500	 
	 July 1, 2011 – December 31,2012
	  	TBD	  	 	TBD	 

 (b) Payment Terms. Client shall pay to Consultant the Consultation Fee on a monthly basis. All payments
shall be made by Client to Consultant via check or wire transfer (Consultant to separately provide wire transfer details). All payments shall be in U.S. Dollars. 

(c) CPS Scientific Bonus Plan. During the Term, Consultant will be eligible to participate in the CPS Scientific Bonus Plan, subject to
the terms and conditions set forth therein. Any bonus that Consultant becomes eligible to receive under the plan will be paid to Consultant within two (2) months following the end of the applicable calendar year. A copy of the Cellectis
Scientific Bonus Plan will be separately provided to Consultant within a reasonable time following the Effective Date. 
 (d) CPS
Commercial Bonus Plan. During the Term, Consultant will be eligible to participate in the CPS Commercial Bonus Plan, subject to the terms set forth therein. A copy of the CPS Commercial Bonus Plan will be separately provided to Consultant within
a reasonable time following the Effective Date. 
 (e) Change of Control. Prior to the consummation of a Change of Control, Client
will pay to Consultant the total Bonus Amount due to Consultant under the CPS Scientific and CPS Commercial Bonus Plan to which Consultant is entitled. CPS Scientific and CPS Commercial Bonus Plan will vest upon Change of Control. For purposes of
this Agreement, “Change of Control” means a majority of the ownership interests or assets (by value) of Client shall have been transferred by sale, operation of law, or other disposition, including merger or consolidation of
Client (other than to an affiliate of Client). 

  
 2 

 (f) No Right to Subcontract. Consultant shall not have the right to subcontract any
Services to be provided by it hereunder without the express prior written consent of Client, which may be withheld in Client’s sole discretion. 

3. Relationship of Parties. 

(a) Independent Contractor. Consultant is an independent contractor and is not an agent or employee of, and has no authority to bind,
Client by contract or otherwise. Consultant will perform the Services under the general direction of Client, but Consultant shall determine, in Consultant’s sole discretion, the manner and means by which the Services are accomplished, subject
to the requirement that Consultant shall at all times comply with applicable law. 
 (b) Employment Taxes. If any payment required to
be made hereunder is subject to any withholding taxes imposed by any governmental authority, Consultant shall pay such taxes to the relevant authorities as required by law. 

4. Intellectual Property Rights. Consultant agrees that it will promptly make full written disclosure to Client, hold in trust for the
sole right and benefit of Client, and does hereby assign to Client, or its designee, all its right, title, and interest in and to any and all inventions, original works of authorship, developments, concepts, improvements, designs, discoveries,
ideas, trademarks and trade secrets, whether or not patentable or registrable under copyright, trademark or similar laws, which Consultant may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or
reduced to practice, in the course of its performance of Services for Client (collectively referred to as “Work Product”). Consultant further acknowledges that, to the extent permitted by law, all original works of authorship
which are made by it (solely or jointly with others) in the course of its performance of Services for Client under this Agreement and which are protectable by copyright shall be deemed “works made for hire,” as that term is defined in the
United States Copyright Act. Consultant understands and agrees that the decision whether or not to commercialize or market any Work Product is within Client’s sole discretion and for Client’s sole benefit and that no royalty will be due to
Consultant as a result of Client’s efforts to commercialize or market any such Work Product. Consultant agrees to provide Client such assistance as is reasonably necessary to obtain or perfect any such rights, including but not limited to
executing and delivering to Client any documents required to apply for patents, register copyrights or to obtain other protections, upon Client’s request and at Client’s sole expense. Consultant forever waives and releases to Client all
rights and benefits accorded under any law with respect to Work Product, including but not limited to the law known as “droit moral,” unfair competition or trade secret laws, or any similar provisions. Client, within its sole
discretion, will be entitled to itself amend, change or modify any Work Product or to engage any third party to amend, change or modify any Work Product. 

  
 3 

 5. Confidential Information. 

(a) Each party (“Recipient”) acknowledges that it may acquire information and materials from the other
party (“Discloser”) and knowledge about trade secrets and know-how of the other party contained in the business, activities and strategies of the Recipient and that all such knowledge and information acquired are and will be
the confidential and proprietary information of Discloser (collectively, the “Confidential Information”). Recipient agrees to hold all such Confidential Information in strict confidence, and not to disclose it to others or
use it in any way, commercially or otherwise, except that Recipient may disclose it to Recipient’s employees and subcontractors on a need-to-know basis and only to employees and subcontractors who are under a like obligation of confidentiality,
and not to allow any unauthorized person access to it, either before or after expiration or termination of this Agreement. Recipient further agrees to use commercially reasonable efforts to protect the confidentiality of the Confidential Information
including, without limitation, implementing and enforcing operating procedures to minimize the possibility of unauthorized use or copying of the Confidential Information.  

(b) Notwithstanding the foregoing, this Agreement imposes no obligation upon Recipient with respect to Confidential Information, which the
Recipient can show by competent documentation, that (i) was in Recipient’s possession before receipt from Discloser; (ii) is or becomes a matter of public knowledge through no fault of Recipient; (iii) is rightfully received by
Recipient from a third party without a duty of confidentiality; (iv) is disclosed by Discloser to a third party without a duty of confidentiality on the third party; (v) is independently developed by Recipient without use of or reference
to such Confidential Information; (vi) is disclosed by Discloser with Recipient’s prior written approval; or (vii) is required to be disclosed by a government body or court of law. If Recipient is required by a government body or
court of law to disclose Confidential Information, prior to such required disclosure, Recipient shall give Discloser reasonable advance notice of any such disclosure and shall cooperate with Discloser in protecting against any such disclosure and/or
obtaining a protective order narrowing the scope of the such disclosure and/or use of the Confidential Information. 

  
 4 

 6. Termination and Expiration. 

(a) Term. The term of this Agreement will commence on the Effective Date and continue for a period of three (3) years thereafter,
unless terminated earlier in accordance with this Section 6 (the “Term”). 
 (b) By Client. 

 

	 	(i)	This Agreement may be terminated by the Client at any time, for any reason or no reason, by written notice to Consultant, subject to Section 6(d) below; and 

 

	 	(ii)	Client may terminate this Agreement with immediate effect if Consultant fails to obtain the approvals set forth in Section 8(b)(ii) herein. In the event of such termination, Section 6(d) shall be null and void
and of no effect. 

 (c) Material Breach. In the event of a material breach or material default of this Agreement by
either party, the non-breaching party shall give the breaching party written notice of the material breach or material default. The breaching party will then have thirty (30) days to cure the material breach or material default, and if cure has
not been affected within said thirty (30) days, this Agreement may, within the sole discretion of the non-breaching party, automatically terminate, effective as of the date specified in the notice. All termination rights shall be in addition to
and not in substitution for any other remedies that may be available to the non-breaching party. 
 (d) Termination Payment and
Release. Upon termination of this Agreement pursuant to Section 6(b)(i) herein, Client shall pay to Consultant a lump-sum payment in an amount equal to: (i) $15,000 if such termination occurs prior to June 30, 2010;
(ii) $37,500 if such termination occurs after June 30, 2010 but before June 30, 2011; or (iii) three (3) months of Consultation Fees if such termination occurs after June 30, 2011 but before the end of the Term.
Notwithstanding anything herein to the contrary, Client will not be obligated to make any payment or provide any benefit under this Section 6(d) hereof unless (1) Consultant executes a release of all current or future claims, known or
unknown, arising on or before the date of the release against Client and its subsidiaries and the directors, officers, employees and affiliates of any of them, in a form approved by Client, and (2) Consultant does not revoke such release during
any applicable revocation period. 

  
 5 

 (e) Accrued Rights. Termination of this Agreement for any reason does not relieve either
party of any obligation or liabilities accrued prior to the termination or rescind anything done by either party and the termination does not affect in any manner any rights of either party arising under this Agreement prior to the termination. 

(f) Survival. Upon the expiration or termination of this Agreement for any reason, the rights and obligations of the parties under the
following Sections of the Agreement shall survive: 3(b ), 4, 5, 6( e ), 6(f), 7, 8, 9, 10, and 11. Section 6(d) shall also survive termination of this Agreement unless such termination is pursuant to Section 6(b )(ii). 

7. Limitation of Liability. EXCEPT FOR A BREACH OF SECTION 5 (CONFIDENTIAL INFORMATION), SECTION 8 (REPRESENTATIONS AND WARRANTIES), OR
SECTION 9 (INDEMNIFICATION), IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES OF ANY KIND OR NATURE WHATSOEVER, INCLUDING WITHOUT LIMITATION, LOSS OF PROFITS OR OTHER
ECONOMIC LOSS, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED, HOWEVER, THAT NEITHER PARTY’S LIABILITY SHALL BE SO LIMITED IN THE EVENT SUCH DAMAGES ARISE DIRECTLY FROM SUCH PARTY’S FRAUD, GROSS NEGLIGENCE
OR WILLFUL MISCONDUCT. EXCEPT FOR A BREACH OF SECTION 5 (CONFIDENTIAL INFORMATION), SECTION 8 (REPRESENTATIONS AND WARRANTIES), OR SECTION 9 (INDEMNIFICATION), THE COLLECTIVE LIABILITY OF EITHER PARTY UNDER THIS AGREEMENT SHALL BE LIMITED TO THE
AMOUNT ACTUALLY PAID BY CLIENT TO CONSULTANT HEREUNDER DURING THE TWELVE (12) MONTH PERIOD IMMEDIATELY PRECEDING THE CLAIM. 

  
 6 

 8. Representations and Warranties. 

(a) General. In addition to the other representations and warranties set forth herein, each party hereto represents and warrants as of
the Effective Date to each other party hereto that (i) each party hereto has the full and entire right, power, and authority (1) to enter into this Agreement, (2) to fulfill the obligations imposed herein upon such party, and
(3) to consummate the transactions contemplated herein, (ii) this Agreement constitutes the legal, valid, and binding obligation of each party hereto, enforceable against such party in accordance with its terms, and (iii) there are no
agreements, contracts, understandings or commitments which would prevent each party hereto from entering into this Agreement, making any representations or warranties herein, and/or consummating any of the transactions contemplated herein. 

(b) By Consultant. In addition to the other representations and warranties set forth herein, Consultant represents and warrants to
Client that Consultant: (i) has and will continue during the Term to comply with all college and university policies at which Consultant is a faculty member in any capacity or with which Consultant is otherwise affiliated
(“Universities”); (ii) has or will make all necessary disclosures to and obtain all necessary approvals (including any special exemptions) from all such Universities prior to performing any Services for Client; and
(iii) has not and will not use any of the Universities’ resources (including facilities, equipment, students or faculty) in the performance of any Services for Client (iiii) has full capacity to assign to Client all its right, title
and interest in and to any and all Work Product. 
 9. Indemnification. Consultant will indemnify the Client and hold it harmless
from and against all claims, damages, losses and expenses, including court costs and reasonable fees and expenses of attorneys, expert witnesses and other professionals, arising out of or resulting from: (a) any action by a third party against
the Client that is based on any claim that any Services performed by Consultant under this Agreement, or their results, infringe a patent, copyright or other proprietary right, misappropriate a trade secret or breach an agreement; and (b) any
action by a third party that is based on any negligent act or omission or willful conduct of Consultant and winch results in: (i) any bodily injury, sickness, disease or death; (ii) any damage or destruction to tangible or intangible
property (including computer programs and data) or any loss of use resulting therefrom; or (iii) any violation of any statute, ordinance, law or regulation. 

  
 7 

 10. Non-Solicitation and Non-Competition by Consultant. Consultant agrees that during the
Term and for a period of one (1) year thereafter, Consultant shall not either directly or indirectly (a) solicit, induce, recruit or encourage any of Client’s employees, consultants or contractors to terminate their relationship with
Client, or (b) attempt to solicit, induce, recruit, encourage or take away employees, consultants or contractors of Client, either for itself or for any other person or entity. Consultant agrees that during the Term and for a period of one
(1) year thereafter, Consultant shall not either directly or indirectly engage or participate in a business (including owning greater than 1% of the outstanding shares of such, business) that is a competitor of Client or work or perform
services for, or assist any person or entity engaged in the Client Business. Notwithstanding the foregoing, Consultant shall not be prohibited from performing similar services for the University of Minnesota; provided that the performance of such
services is for academic and research purposes only and does not otherwise breach this Agreement. 
 11. General. 

(a) Assignment. Except as otherwise set forth herein, neither party may assign its rights or delegate its duties under this Agreement
either in whole or in part without the prior written consent of the other party; provided, however, that Client may assign its rights or delegate its duties under this Agreement in whole or in part without the consent of Consultant in the event of a
sale of all or substantially all of Client’s assets, merger, consolidation or other Change of Control of Client. Any attempted assignment or delegation without such consent will be void. 

(b) Equitable Remedies. Because the Services are personal and unique and because each party will have access to Confidential
Information of the other party, each party will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief without prejudice to any other rights and remedies that such party may
have for a breach of this Agreement. 
 (c) Attorneys’ Fees. If any action is necessary to enforce the terms of this Agreement,
the substantially prevailing party will be entitled to reasonable attorneys’ fees, costs and expenses in addition to any other relief to which such prevailing party may be entitled. 

  
 8 

 (d) Choice of Law. This Agreement will be governed by, and construed in accordance with,
the internal, substantive laws of the State of Delaware. Each party agrees that the state and federal courts located in the State of New York will have jurisdiction in any action, suit or proceeding against Consultant based on or arising out of this
Agreement and each party hereby: (i) submits to the personal jurisdiction of such courts; (ii) consents to service of process in connection with any action, suit or proceeding against the other party; and (iii) waives any other
requirement (whether imposed by statute, rule of court or otherwise) with respect to personal jurisdiction, venue or service of process. 

(e) Notices. Any notices under this Agreement will be sent by nationally recognized overnight delivery service to the address specified
below or such other address as the party specifies in writing. Such notice will be effective upon delivery to the other party. 
 (f)
Complete Understanding; Modification. This Agreement, together with all exhibits constitutes the complete and exclusive understanding and agreement of the parties and supersedes all prior understandings and agreements, whether written or
oral, with respect to the subject matter hereof. Any waiver, modification or amendment of any provision of this Agreement will be effective only if in writing and signed by the parties hereto. The invalidity or unenforceability of any particular
provision of this Agreement shall not affect the other provisions hereof, and this Agreement shall be construed in all respects as if such invalid or unenforceable provisions were omitted. 

(g) Counterparts. This Agreement may be executed in two (2) counterparts, each of which will be considered an original, but both
of which together will constitute one and the same instrument. 
 [Signature Page Follows] 

  
 9 

 IN WITNESS WHEREOF, Client has caused this Consulting Agreement to be signed by its duly
authorized representative, and Consultant has signed this Consulting Agreement, as of the date first set forth above. 
  

									
	CLIENT:	 		 	CONSULTANT:
			
	CELLECTIS PLANT SCIENCES, INC.	 		 	DAN VOYTAS
					
	By:	 	/s/ David Sourdive	 		 	By:	 	/s/ Dan Voytas
		 	David Sourdive, Director	 		 		 	Dan Voytas

  
 10 

 EXHIBIT A 

Services Description 
 (a)
top level planning of projects including CPS business plan preparation 
 (b) analysis of results in the context of project review meetings

 (c) contribute to the strategy of developing a unique position for CPS in agricultural R&D 

(d) advising on new emerging technologies in the Field to adopt 

(e) scientific support during business development missions 

(f) run the scientific advisory board

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]